The board of NTP Radioisotopes (NTP) has announced the reinstatement of three of its senior executives following the conclusion of an inquiry into a breach of safety regulations at the NTP radiochemicals complex in 2017. NTP is a global producer and supplier of nuclear medicine and radiation-based products and services. The company supplies up to a third of the global demand for Mo-99, the most widely used isotope. Mo-99 is used in the diagnosis of cancer. The company exports about 90% of its products and generates about R3.5m a day. In November 2017, the National Nuclear Regulator ordered the South African Nuclear Energy Corporation to shut down production at its NTP radiochemicals complex for violating safety procedures. This came after NTP’s hydrogen monitoring systems failed. Hydrogen is highly flammable and has to be closely monitored. The failure could have resulted in an explosion, the regulator said. NTP had only reported the systems failure three days after it occurred in O...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, Morningstar financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00.